miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells

Dynoodt,Peter; Speeckaert,Reinhart; De Wever,Olivier; Chevolet,Inès; Brochez,Lieve; Lambert,Jo; Van Gele,Mireille

doi:10.3892/ijo.2013.1823

miR-145 overexpression suppresses the migration and invasion of metastatic melanoma cells

Authors:
- Peter Dynoodt
- Reinhart Speeckaert
- Olivier De Wever
- Inès Chevolet
- Lieve Brochez
- Jo Lambert
- Mireille Van Gele
View Affiliations

Affiliations: Department of Dermatology, Ghent University Hospital, 9000 Ghent, Belgium, Laboratory of Experimental Cancer Research, Department of Radiotherapy and Nuclear Medicine, Ghent University Hospital, 9000 Ghent, Belgium
Published online on: February 12, 2013 https://doi.org/10.3892/ijo.2013.1823
Pages: 1443-1451

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are post-transcriptional modulators of gene expression which play important roles in tumorigenesis and cancer metastasis. Since they are often highly deregulated in various types of cancer, miRNAs may be effective treatment targets. miRNA profiling studies of melanoma have led to the identification of several tumor suppressor miRNAs. One of these include miR-145, although functional data proving its specific function are limited. Therefore, in this study, we examined the expression levels of miR-145 in three melanoma cell lines (BLM, FM3P and WM793). Additional gain-of-function experiments revealed that miR-145 exerts an anti-proliferative effect in the primary, non-invasive melanoma cell line, WM793, whereas cell migration and the invasive potential of metastatic melanoma cells was suppressed following transfection with miR-145 mimics. In order to investigate the mechanisms by which miR-145 exerts its invasion suppressor function, we examined the expression level of target genes [fascin homolog 1 (FSCN1), myosin‑Va (MYO5A and SOX9] and that of an indirect target (RAB27A) following the overexpression of miR-145. The results showed that SOX9, MYO5A and RAB27A were not involved in the biological effects caused by miR-145 mimics. Surprisingly, we discovered that miR-145 in melanoma, in contrast to many other tumor types, does not necessarily act via the target, FSCN1, since the downregulation of FSCN1 did not inhibit cell proliferation or migration but, on the contrary, increased cell invasion in two out of the three melanoma cell lines examined. Our in vitro data is in accordance with previously reported in vivo data describing the low expression of FSCN1 in malignant melanomas when compared to dysplastic nevi, suggesting that the expression of FSCN1 decreases as the formation and progression stage of melanoma advances. In conclusion, our data provide evidence that miR-145 is an invasion suppressor in metastatic melanoma cells. Despite the fact that it remains unclear which genes or pathways are regulated by miR-145 in melanoma, miR-145 may serve as a useful therapeutic agent in melanoma when re-expressed in situ.

View Figures

View References

1	Garbe C and Leiter U: Melanoma epidemiology and trends. Clin Dermatol. 27:3–9. 2009. View Article : Google Scholar
2	Chin L: The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer. 3:559–570. 2003. View Article : Google Scholar : PubMed/NCBI
3	Lin K, Baritaki S, Militello L, Malaponte G, Bevelacqua Y and Bonavida B: The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-κB/Snail/RKIP/PTEN circuit. Genes Cancer. 1:409–420. 2010.PubMed/NCBI
4	Howell PM Jr, Li X, Riker AI and Xi Y: MicroRNA in melanoma. Ochsner J. 10:83–92. 2010.PubMed/NCBI
5	Mueller DW and Bosserhoff AK: Role of miRNAs in the progression of malignant melanoma. Br J Cancer. 101:551–556. 2009. View Article : Google Scholar : PubMed/NCBI
6	Mueller DW and Bosserhoff AK: The evolving concept of ‘melano-miRs’-microRNAs in melanomagenesis. Pigment Cell Melanoma Res. 23:620–626. 2010.
7	Molnár V, Tamási V, Bakos B, Wiener Z and Falus A: Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin Cancer Biol. 18:111–122. 2008.PubMed/NCBI
8	Segura MF, Belitskaya-Lévy I, Rose AE, et al: Melanoma microRNA signature predicts post-recurrence survival. Clin Cancer Res. 16:1577–1586. 2010. View Article : Google Scholar : PubMed/NCBI
9	Sachdeva M and Mo YY: miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res. 2:170–180. 2010.PubMed/NCBI
10	Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
11	Noguchi S, Mori T, Hoshino Y, et al: Comparative study of anti-oncogenic microRNA-145 in canine and human malignant melanoma. J Vet Med Sci. 74:1–8. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kirkin AF, Petersen TR, Olsen AC, Li L, thor Straten P and Zeuthen J: Generation of human-melanoma-specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother. 41:71–81. 1995. View Article : Google Scholar
13	Naeyaert JM, Eller M, Gordon PR, Park HY and Gilchrest BA: Pigment content of cultured human melanocytes does not correlate with tyrosinase message level. Br J Dermatol. 125:297–303. 1991. View Article : Google Scholar : PubMed/NCBI
14	Van Gele M, Geusens B, Schmitt AM, Aguilar L and Lambert J: Knockdown of myosin Va isoforms by RNAi as a tool to block melanosome transport in primary human melanocytes. J Invest Dermatol. 128:2474–2484. 2008.PubMed/NCBI
15	Vandesompele J, De Paepe A and Speleman F: Elimination of primer-dimer artifacts and genomic coamplification using a two-step SYBR green I real-time RT-PCR. Anal Biochem. 303:95–98. 2002. View Article : Google Scholar : PubMed/NCBI
16	Vandesompele J, De Preter K, Pattyn F, et al: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3:Research00342002. View Article : Google Scholar : PubMed/NCBI
17	De Wever O, Hendrix A, De Boeck A, et al: Modeling and quantification of cancer cell invasion through collagen type I matrices. Int J Dev Biol. 54:887–896. 2010.PubMed/NCBI
18	Dynoodt P, Mestdagh P, Van Peer G, et al: Identification of miR-145 as a key regulator of the pigmentary process. J Invest Dermatol. August 16–2012.(E-pub ahead of print). View Article : Google Scholar
19	Chiyomaru T, Enokida H, Tatarano S, et al: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
20	Fuse M, Nohata N, Kojima S, et al: Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 38:1093–1101. 2011.PubMed/NCBI
21	Kim SJ, Oh JS, Shin JY, et al: Development of microRNA-145 for therapeutic application in breast cancer. J Control Release. 155:427–434. 2011. View Article : Google Scholar : PubMed/NCBI
22	Mascellani N, Tagliavini L, Gamberoni G, et al: Using miRNA expression data for the study of human cancer. Minerva Biotec. 20:23–30. 2008.
23	Sachdeva M, Zhu S, Wu F, et al: p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA. 106:3207–3212. 2009. View Article : Google Scholar : PubMed/NCBI
24	Sachdeva M and Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res. 70:378–387. 2010. View Article : Google Scholar : PubMed/NCBI
25	Yang B, Guo H, Zhang Y, Chen L, Ying D and Dong S: MicroRNA-145 regulates chondrogenic differentiation of mesenchymal stem cells by targeting Sox9. PLoS One. 6:e216792011. View Article : Google Scholar : PubMed/NCBI
26	Kureishy N, Sapountzi V, Prag S, Anilkumar N and Adams JC: Fascins, and their roles in cell structure and function. Bioessays. 24:350–361. 2002. View Article : Google Scholar : PubMed/NCBI
27	Hashimoto Y, Skacel M and Adams JC: Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol. 37:1787–1804. 2005. View Article : Google Scholar : PubMed/NCBI
28	Yildiz L, Kefeli M, Aydin O and Kandemir B: Fascin expression in melanocytic lesions of the skin. Eur J Dermatol. 19:445–450. 2009.PubMed/NCBI
29	Goncharuk VN, Ross JS and Carlson JA: Actin-binding protein fascin expression in skin neoplasia. J Cutan Pathol. 29:430–438. 2002. View Article : Google Scholar : PubMed/NCBI
30	Zhang J, Guo H, Zhang H, et al: Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene. Cancer. 117:86–95. 2011. View Article : Google Scholar : PubMed/NCBI
31	Götte M, Mohr C, Koo CY, et al: miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene. 29:6569–6580. 2010.PubMed/NCBI